Perspective Therapeutics (CATX) Cash from Investing Activities (2010 - 2026)

Perspective Therapeutics has disclosed Cash from Investing Activities across 17 years of filings, most recently posting -$109.6 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$109.6 million, down 1868.61% year-over-year; the trailing twelve-month figure through Mar 2026 was -$62.8 million (up 64.58% YoY), and the FY2025 annual result was $41.2 million, up 118.83% from the prior year.
• Cash from Investing Activities came in at -$109.6 million for Q1 2026 at Perspective Therapeutics, down from $28.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $28.5 million in Q4 2025 to a low of -$138.6 million in Q4 2024.
• The 5-year median for Cash from Investing Activities is -$573000.0 (2023), against an average of -$19.2 million.
• Across the five-year window, Cash from Investing Activities soared 97261.54% in 2023 and slumped 155632.58% in 2024, its largest moves.
• Perspective Therapeutics' Cash from Investing Activities stood at -$28.8 million in 2022, then surged by 99.69% to -$89000.0 in 2023, then plunged by 155632.58% to -$138.6 million in 2024, then soared by 120.59% to $28.5 million in 2025, then plunged by 483.9% to -$109.6 million in 2026.
• The last three Cash from Investing Activities figures came in at -$109.6 million (Q1 2026), $28.5 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.